lactic acid has been researched along with Inflammatory Bowel Diseases in 24 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dimethilhydrazine was used to induce colorectal cancer in mice." | 5.46 | Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model. ( Azevedo, V; Bermúdez-Humarán, LG; de Moreno de LeBlanc, A; Del Carmen, S; Langella, P; LeBlanc, JG; Levit, R, 2017) |
| " The present paper describes cases of diseases caused by lactic acid bacteria, a potential mechanism for the adverse action of bacteria, and the possible hazard connected with probiotic supplementation for seriously ill and hospitalized patients." | 2.50 | [Lactic acid bacteria and health: are probiotics safe for human?]. ( Gackowska, L; Januszewska, M; Kubiszewska, I; Rybka, J, 2014) |
| "Malignant tumors, such as colorectal cancer (CRC), are heterogeneous diseases characterized by distinct metabolic phenotypes." | 1.48 | Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells. ( Ammar, N; Arlt, A; Diehl, K; Dinges, LA; Helm, O; Plundrich, D; Röcken, C; Schäfer, H; Sebens, S, 2018) |
| "The therapy of inflammatory bowel diseases is still rather inefficient, and about 80% of patients require surgery at some stage." | 1.46 | Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. ( Carreras, JJ; Draheim, C; Garrigues, TM; Giner, E; Giner, R; Hansen, S; Lehr, CM; Melero, A; Peris, JE; Recio, MC; Talens-Visconti, R, 2017) |
| "Dimethilhydrazine was used to induce colorectal cancer in mice." | 1.46 | Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model. ( Azevedo, V; Bermúdez-Humarán, LG; de Moreno de LeBlanc, A; Del Carmen, S; Langella, P; LeBlanc, JG; Levit, R, 2017) |
| "Curcumin (CC) is an anti-inflammatory local agent, which presents poor ADME properties." | 1.40 | pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. ( Beloqui, A; Coco, R; des Rieux, A; Memvanga, PB; Préat, V; Ucakar, B, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 16 (66.67) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Q | 1 |
| Gao, X | 1 |
| Wu, J | 1 |
| Chen, M | 1 |
| Manoharan, I | 1 |
| Prasad, PD | 1 |
| Thangaraju, M | 1 |
| Manicassamy, S | 1 |
| Melero, A | 1 |
| Draheim, C | 1 |
| Hansen, S | 1 |
| Giner, E | 1 |
| Carreras, JJ | 1 |
| Talens-Visconti, R | 1 |
| Garrigues, TM | 1 |
| Peris, JE | 1 |
| Recio, MC | 1 |
| Giner, R | 1 |
| Lehr, CM | 5 |
| Diehl, K | 1 |
| Dinges, LA | 1 |
| Helm, O | 1 |
| Ammar, N | 1 |
| Plundrich, D | 1 |
| Arlt, A | 1 |
| Röcken, C | 1 |
| Sebens, S | 1 |
| Schäfer, H | 1 |
| He, L | 1 |
| Wang, H | 1 |
| Zhang, Y | 1 |
| Geng, L | 1 |
| Yang, M | 1 |
| Xu, Z | 1 |
| Zou, K | 1 |
| Xu, W | 1 |
| Gong, S | 1 |
| Ali, H | 3 |
| Weigmann, B | 2 |
| Neurath, MF | 1 |
| Collnot, EM | 3 |
| Windbergs, M | 2 |
| Beloqui, A | 1 |
| Coco, R | 2 |
| Memvanga, PB | 1 |
| Ucakar, B | 1 |
| des Rieux, A | 1 |
| Préat, V | 2 |
| Kubiszewska, I | 1 |
| Januszewska, M | 1 |
| Rybka, J | 1 |
| Gackowska, L | 1 |
| Saez-Lara, MJ | 1 |
| Gomez-Llorente, C | 1 |
| Plaza-Diaz, J | 1 |
| Gil, A | 1 |
| Khan, SA | 1 |
| Del Carmen, S | 1 |
| de Moreno de LeBlanc, A | 1 |
| Levit, R | 1 |
| Azevedo, V | 1 |
| Langella, P | 1 |
| Bermúdez-Humarán, LG | 1 |
| LeBlanc, JG | 1 |
| Song, WB | 1 |
| Lv, YH | 1 |
| Zhang, ZS | 1 |
| Li, YN | 1 |
| Xiao, LP | 1 |
| Yu, XP | 1 |
| Wang, YY | 1 |
| Ji, HL | 1 |
| Ma, L | 1 |
| Schmidt, EG | 1 |
| Claesson, MH | 1 |
| Jensen, SS | 1 |
| Ravn, P | 1 |
| Kristensen, NN | 1 |
| Xie, Q | 1 |
| Gan, HT | 1 |
| Tahara, K | 1 |
| Samura, S | 1 |
| Tsuji, K | 1 |
| Yamamoto, H | 2 |
| Tsukada, Y | 1 |
| Bando, Y | 1 |
| Tsujimoto, H | 1 |
| Morishita, R | 1 |
| Kawashima, Y | 2 |
| Scheijen, JL | 1 |
| Hanssen, NM | 1 |
| van de Waarenburg, MP | 1 |
| Jonkers, DM | 1 |
| Stehouwer, CD | 1 |
| Schalkwijk, CG | 1 |
| Plapied, L | 1 |
| Pourcelle, V | 1 |
| Jérôme, C | 1 |
| Brayden, DJ | 1 |
| Schneider, YJ | 1 |
| Leonard, F | 1 |
| Crielaard, BJ | 1 |
| Lammers, T | 1 |
| Storm, G | 1 |
| Park, K | 1 |
| Hanniffy, S | 1 |
| Wiedermann, U | 1 |
| Repa, A | 1 |
| Mercenier, A | 1 |
| Daniel, C | 1 |
| Fioramonti, J | 1 |
| Tlaskolova, H | 1 |
| Kozakova, H | 1 |
| Israelsen, H | 1 |
| Madsen, S | 1 |
| Vrang, A | 1 |
| Hols, P | 1 |
| Delcour, J | 1 |
| Bron, P | 1 |
| Kleerebezem, M | 1 |
| Wells, J | 1 |
| Heyman, M | 1 |
| Terpend, K | 1 |
| Ménard, S | 1 |
| Hove, H | 1 |
| Mortensen, PB | 1 |
| Treem, WR | 1 |
| Ahsan, N | 1 |
| Shoup, M | 1 |
| Hyams, JS | 1 |
| Lamprecht, A | 1 |
| Ubrich, N | 1 |
| Schäfer, U | 1 |
| Takeuchi, H | 1 |
| Maincent, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center Clinical Research About Standard Diagnosis and Treatment of Neonate Severe Digestive System Malformation[NCT02699320] | 33 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for lactic acid and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Lactate-Dependent Regulation of Immune Responses by Dendritic Cells and Macrophages.
Topics: Animals; Autoimmunity; Cell Cycle Proteins; Dendritic Cells; Humans; Immunomodulation; Infections; I | 2021 |
[Lactic acid bacteria and health: are probiotics safe for human?].
Topics: Bifidobacterium; Gastrointestinal Diseases; Health Status; Humans; Immune System; Inflammatory Bowel | 2014 |
The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials.
Topics: Animals; Bifidobacterium; Humans; Inflammatory Bowel Diseases; Lactic Acid; Lactobacillales; Probiot | 2015 |
Potential and opportunities for use of recombinant lactic acid bacteria in human health.
Topics: Animals; Communicable Disease Control; DNA, Recombinant; Health; Humans; Hypersensitivity, Immediate | 2004 |
20 other studies available for lactic acid and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
The Correlation between Endotoxin, D-Lactate, and Diamine Oxidase with Endoscopic Activity in Inflammatory Bowel Disease.
Topics: Amine Oxidase (Copper-Containing); Biomarkers; C-Reactive Protein; Colitis, Ulcerative; Crohn Diseas | 2022 |
Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model.
Topics: Administration, Oral; Animals; Biological Availability; Colon; Cyclosporine; Disease Models, Animal; | 2017 |
Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells.
Topics: Apoptosis; Biopsy; Cell Line, Tumor; Cell Transformation, Neoplastic; Coculture Techniques; Colon; C | 2018 |
Evaluation of Monocarboxylate Transporter 4 in Inflammatory Bowel Disease and Its Potential Use as a Diagnostic Marker.
Topics: Adolescent; Biomarkers; Case-Control Studies; Child; Child, Preschool; Female; Humans; Infant; Infla | 2018 |
Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
Topics: Animals; Anti-Inflammatory Agents; Budesonide; Cytokines; Disease Models, Animal; Drug Carriers; Dru | 2014 |
pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Caco-2 Cells; Cell Line; Colitis; Colon; Curcumin; Dextran Sulfat | 2014 |
Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
Topics: Animals; Anti-Inflammatory Agents; Budesonide; Colitis; Drug Carriers; Drug Delivery Systems; Drug L | 2016 |
Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model.
Topics: Animals; Antineoplastic Agents; Antioxidants; Catalase; Colorectal Neoplasms; Disease Models, Animal | 2017 |
Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease.
Topics: Adolescent; Adult; Amine Oxidase (Copper-Containing); Female; Humans; Inflammatory Bowel Diseases; I | 2009 |
Antigen-presenting cells exposed to Lactobacillus acidophilus NCFM, Bifidobacterium bifidum BI-98, and BI-504 reduce regulatory T cell activity.
Topics: Animals; Antigen-Presenting Cells; Antigens, Bacterial; Bifidobacterium; CD4-Positive T-Lymphocytes; | 2010 |
Controversies about the use of serological markers in diagnosis of inflammatory bowel disease.
Topics: Amine Oxidase (Copper-Containing); Biomarkers; Humans; Inflammatory Bowel Diseases; Intercellular Ad | 2010 |
Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease.
Topics: Animals; Chitosan; Drug Carriers; Inflammatory Bowel Diseases; Lactic Acid; Male; Nanospheres; NF-ka | 2011 |
L(+) and D(-) lactate are increased in plasma and urine samples of type 2 diabetes as measured by a simultaneous quantification of L(+) and D(-) lactate by reversed-phase liquid chromatography tandem mass spectrometry.
Topics: Adult; Aged; Chromatography, Reverse-Phase; Diabetes Mellitus, Type 2; Female; Humans; Inflammatory | 2012 |
Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.
Topics: Animals; Caco-2 Cells; Chitosan; Colitis; Cytokines; Dextran Sulfate; Drug Carriers; Ethylene Oxide; | 2013 |
Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model.
Topics: Animal Testing Alternatives; Anti-Inflammatory Agents; Budesonide; Caco-2 Cells; Cells, Cultured; Co | 2012 |
Targeted delivery nano/micro particles to inflamed intestinal mucosa in human.
Topics: Drug Carriers; Drug Delivery Systems; Humans; Inflammatory Bowel Diseases; Intestinal Mucosa; Lactic | 2013 |
Effects of specific lactic acid bacteria on the intestinal permeability to macromolecules and the inflammatory condition.
Topics: Bifidobacterium; Biological Transport; Cell Membrane Permeability; Health Promotion; Humans; Infant; | 2005 |
Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Child; Chromatography, Gas; Fatty | 1995 |
Fecal short-chain fatty acids in children with inflammatory bowel disease.
Topics: Adolescent; Adult; Child; Chromatography, Gas; Colitis, Ulcerative; Colon; Crohn Disease; Fatty Acid | 1994 |
Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Colon; Drug Carriers; Drug Delivery S | 2001 |